TokenPost·
FDA Approves Perioperative Durvalumab-Padcev for Cisplatin-Ineligible MIBC
The approval covers perioperative use in patients who cannot receive cisplatin-based chemotherapy.
More news
- TokenPostMingteng International Posts $5.51 Million First-Half Revenue
- TokenPostSiebert Financial Advisory Fees Climb 38% to $1.1 Million in Q3
- TokenPostAmerican Strategic Investment Lists Q3 Results Announcement Dated Nov. 13
- Bitcoin.com NewsTwenty One Capital’s Bitcoin Gains Fuel First Profitable Quarter at $1.09B
- TokenPostU.S. Oil and Gas Rig Count Falls by Three to 601 in Weekly Survey
- TokenPostMirendil Raises $1 Billion Series A to Broaden Access to AI Research